20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Procept Biorobotics Corp (PRCT) operates in the MEDICAL DEVICES industry and is headquartered in San Jose, United States with about 888 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, PRCT reported $308M in revenue and ($96M) in net income.
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally.
Interactive charts & full statements → Open the PRCT valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $336M | $308M | $224M | $136M | $75M | $34M | $8M | $6M |
| Gross Profit | $214M | $196M | $137M | $71M | $37M | $16M | ($1M) | ($2M) |
| Gross Margin % | 63.7% | 63.7% | 61.1% | 52.2% | 49.4% | 46.0% | -16.3% | -30.6% |
| Operating Income (EBIT) | ($114M) | ($104M) | ($97M) | ($109M) | ($81M) | ($54M) | ($48M) | ($44M) |
| Operating Margin % | -33.9% | -33.7% | -43.0% | -80.2% | -107.6% | -157.1% | -619.4% | -706.0% |
| Net Income | ($110M) | ($96M) | ($91M) | ($106M) | ($87M) | ($60M) | ($53M) | ($42M) |
| Net Margin % | -32.7% | -31.0% | -40.7% | -77.8% | -116.2% | -173.6% | -687.0% | -680.4% |
| EBITDA | ($99M) | ($85M) | ($82M) | ($98M) | ($79M) | ($51M) | ($45M) | ($40M) |
| Earnings Per Share (EPS) | $-1.95 | $-1.72 | $-1.75 | $-2.24 | $-1.96 | $-1.37 | $-1.51 | $-1.25 |
| Shares Outstanding (M) | 57M | 56M | 52M | 47M | 44M | 44M | 35M | 34M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $94M | $83M | $76M | $83M | $79M | $69M | $68M | $58M |
| Gross Profit | $62M | $54M | $46M | $52M | $50M | $44M | $44M | $37M |
| Gross Margin % | 66.0% | 64.9% | 60.6% | 62.9% | 63.3% | 63.8% | 64.0% | 63.2% |
| Operating Income (EBIT) | ($27M) | ($33M) | ($31M) | ($23M) | ($22M) | ($27M) | ($20M) | ($22M) |
| Operating Margin % | -29.0% | -39.2% | -40.6% | -27.8% | -28.0% | -39.7% | -28.9% | -38.4% |
| Net Income | ($27M) | ($32M) | ($30M) | ($21M) | ($20M) | ($25M) | ($19M) | ($21M) |
| Net Margin % | -28.4% | -38.1% | -39.1% | -25.7% | -24.7% | -35.8% | -27.6% | -35.9% |
| EBITDA | ($24M) | ($29M) | ($27M) | ($19M) | ($17M) | ($22M) | ($16M) | ($19M) |
| Earnings Per Share (EPS) | $-0.48 | $-0.56 | $-0.53 | $-0.38 | $-0.35 | $-0.45 | $-0.35 | $-0.40 |
| Shares Outstanding (M) | 57M | 57M | 56M | 56M | 55M | 55M | 54M | 52M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($74M) | ($49M) | ($99M) | ($108M) | ($80M) | ($57M) | ($48M) | ($44M) |
| Capital Expenditures (CapEx) | $11M | $9M | $4M | $25M | $3M | $1M | $0M | $8M |
| Free Cash Flow (FCF) | ($85M) | ($58M) | ($104M) | ($133M) | ($83M) | ($58M) | ($49M) | ($51M) |
| FCF Margin % | -25.3% | -18.9% | -46.2% | -97.8% | -110.7% | -168.0% | -629.5% | -833.7% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($19M) | ($38M) | ($10M) | ($7M) | ($15M) | ($17M) | ($32M) | ($19M) |
| Capital Expenditures (CapEx) | $3M | $3M | $2M | $3M | $3M | $2M | $1M | $0M |
| Free Cash Flow (FCF) | ($22M) | ($41M) | ($12M) | ($10M) | ($18M) | ($19M) | ($34M) | ($19M) |
| FCF Margin % | -23.4% | -49.4% | -15.9% | -11.4% | -22.5% | -27.2% | -49.2% | -32.6% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $479M | $508M | $534M | $405M | $309M | $337M | $126M | $62M |
| Cash & Cash Equivalents | $228M | $287M | $334M | $257M | $223M | $304M | $100M | $42M |
| Total Liabilities | $139M | $142M | $132M | $124M | $112M | $70M | $65M | $33M |
| Total Debt (Short + Long-Term) | $54M | $54M | $53M | $53M | $53M | $52M | $51M | $26M |
| Total Shareholders' Equity | $340M | $366M | $402M | $281M | $197M | $267M | $61M | $29M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PRCT viewer.
About TickerBase · Data methodology & sources · Privacy · Terms